Beskrivning av upphandlingen
This procurement is for R&D services to address the following challenge: The overall goal of Live Incite is to improve health outcome of smokers and risky drinkers by reducing postoperative complications through lifestyle interventions with digital services. Live Incite thus challenges the market to develop a digital solution for behavior change that:
1) Supports patients to quit smoking and risky drinking before and after surgery;
2) Can be applied beyond the core case.
The challenge is further specified in the core case and evaluation framework.
The Live Incite PCP is a framework agreement which is implemented by specific contracts, awarded for and covering each specific phase 1, 2, and 3.
We will evaluate four main award criteria: Solution Quality, PCP execution Quality, Financial Compensation for Retention of IPR, and Offered Price.
We have defined four success components for a solution, addressing short as well as long-term aspects:
— Effectiveness: That the solution leads to and enables the desired outcomes,
— Capability: That the solution includes some fundamental functionalities which we have identified as crucial,
— Feasibility: That the solution is practically feasible to implement it,
— Sustainability: That the solution provides the ability to evolve over time.
The PCP will be conducted over 3 phases, starting with publishing the Tender in 1.2018:
Phase 1: Solution design: 7.5.2018 — 24.8.2018.
In the solution design phase, an estimated 4-7 (number not restricted however) tenderers are awarded contract. This phase is a feasibility study of the selected technologies and proposals, which aims to verify the technical, economical and organizational feasibility of each company's offer. The expected outcome from participating companies is a report describing the results of the feasibility study.
Phase 2: Prototype Development: 26.11.2018 — 7.6.2019.
In the Prototype phase, an estimated 3-4 (number not restricted however) contractors (if eligible — defined as having passed the previous phase successfully) are awarded contract to develop a prototype.
Phase 3: Original Development including field test/pilot: 23.9.2019 — 26.6.2020.
An estimated (number not restricted however) 2-3 contractors (if eligible — defined as having passed the previous phase successfully) are awarded contract for the Original Development phase, including 2 parts:
Part 1: Developing a pilot-ready solution.
Part 2: Supporting a pilot (field-test) of the solution, to be run on 3 sites in a real-life clinical setting.
The max budget per contractor and phase: EUR 75 000 (solution design), EUR 400 000 (prototype), EUR 750 000 (orig develop).
Contractors will retain ownership of the Intellectual Property Rights (IPRs) generated during the PCP, provided they have passed the eligibility criteria of providing a financial compensation for such retention of IPR.